MRNA Insider Trading News PRO Moderna CEO Stephane Bancel Discloses Open Market Purchase Of 160,314 Shares At Avg. Price $31.22 Benzinga Newsdesk Moderna, Regeneron Pharmaceuticals And 2 Other Stocks ...

Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today ...

CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. Mr. McDonnell will ...

Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today ...

A suspect has been identified in the investigation into a parcel bombing that seriously wounded a sanctioned Ukraine-born multi-millionaire and two others in Monaco, the principality's prosecutor's ...

Police in Monaco and France launched a manhunt for a suspected bomber on Tuesday after three people were wounded by an explosion in the wealthy principality, including Ukrainian-born oligarch Vadym ...

A makeshift bomb which detonated outside a residential building in Monaco has injured three people, with reports suggesting a Ukrainian tycoon is among them. Police have launched a manhunt to find the ...

Add Yahoo as a preferred source to see more of our stories on Google. Monaco blast not being investigated as 'terrorist' attack, public prosecutor says Authorities in Monaco are investigating an ...

Three people were injured in an apparent parcel bomb attack in central Monaco on Monday evening, triggering a major security operation in the principality. Prince Albert II of Monaco condemned what he ...

Police in Monaco and neighbouring France are hunting for a man suspected of detonating a makeshift bomb in the centre of the wealthy Mediterranean principality, which seriously injured several people, ...

The Horizon programme contains a variety of mRNA assets in varying stages of development, including a preclinical in vivo candidate.